Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
allogeneic TCR-T cell therapy
- Development stage
- Preclinical
- Lead developer
- Lion TCR
- Modality
- TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
Allogeneic TCR-T cell therapy is an "off-the-shelf" cellular immunotherapy program developed by Lion TCR. This platform utilizes T cells from healthy donors that are genetically engineered to express specific T-cell receptors (TCRs) targeting viral antigens, such as those derived from the Hepatitis B Virus (HBV) and Epstein-Barr Virus (EBV). The primary goal is to treat viral-related diseases and associated malignancies, including HBV-related hepatocellular carcinoma (HCC) and EBV-related nasopharyngeal carcinoma, without the need for patient-specific manufacturing. By targeting viral epitopes presented on the surface of infected or cancerous cells, these engineered T cells facilitate targeted cell destruction. The program is currently in the preclinical stage of development and aims to overcome the logistical and cost barriers associated with autologous cell therapies.
- Other names
- Allogeneic T-cell receptor-engineered T cellsOff-the-shelf TCR-T cell therapyAllogeneic TCR-T
02
Targets
MHC I (MHC class I})
Beyond the preview
Go deeper on allogeneic TCR-T cell therapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on allogeneic TCR-T cell therapy.